13
Views
79
CrossRef citations to date
0
Altmetric
Gene Expression

The C Terminus of p53 Family Proteins Is a Cell Fate Determinant

&
Pages 2014-2030 | Received 04 Oct 2004, Accepted 29 Nov 2004, Published online: 27 Mar 2023

REFERENCES

  • Arai, N., D. Nomura, K. Yokota, D. Wolf, E. Brill, O. Shohat, and V. Rotter. 1986. Immunologically distinct p53 molecules generated by alternative splicing. Mol. Cell. Biol. 6:3232–3239.
  • Augustin, M., C. Bamberger, D. Paul, and H. Schmale. 1998. Cloning and chromosomal mapping of the human p53-related KET gene to chromosome 3q27 and its murine homolog Ket to mouse chromosome 16. Mamm. Genome 9:899–902.
  • Bourdon, J. C., V. Deguin-Chambon, J. C. Lelong, P. Dessen, P. May, B. Debuire, and E. May. 1997. Further characterisation of the p53 responsive element—identification of new candidate genes for trans-activation by p53. Oncogene 14:85–94.
  • Brooks, C. L., and W. Gu. 2003. Ubiquitination, phosphorylation and acetylation: the molecular basis for p53 regulation. Curr. Opin. Cell Biol. 15:164–171.
  • Buckbinder, L., R. Talbott, S. Velasco-Miguel, I. Takenaka, B. Faha, B. R. Seizinger, and N. Kley. 1995. Induction of the growth inhibitor IGF-binding protein 3 by p53. Nature 377:646–649.
  • Butt, A. J., S. M. Firth, M. A. King, and R. C. Baxter. 2000. Insulin-like growth factor-binding protein-3 modulates expression of Bax and Bcl-2 and potentiates p53-independent radiation-induced apoptosis in human breast cancer cells. J. Biol. Chem. 275:39174–39181.
  • Candau, R., D. M. Scolnick, P. Darpino, C. Y. Ying, T. D. Halazonetis, and S. L. Berger. 1997. Two tandem and independent sub-activation domains in the amino terminus of p53 require the adaptor complex for activity. Oncogene 15:807–816.
  • Chen, X., L. J. Ko, L. Jayaraman, and C. Prives. 1996. p53 levels, functional domains, and DNA damage determine the extent of the apoptotic response of tumor cells. Genes Dev. 10:2438–2451.
  • Chen, X., Y. Zheng, J. Zhu, J. Jiang, and J. Wang. 2001. p73 is transcriptionally regulated by DNA damage, p53, and p73. Oncogene 20:769–774.
  • Contente, A., A. Dittmer, M. C. Koch, J. Roth, and M. Dobbelstein. 2002. A polymorphic microsatellite that mediates induction of PIG3 by p53. Nat. Genet. 30:315–320.
  • Courtois, S., C. C. de Fromentel, and P. Hainaut. 2004. p53 protein variants: structural and functional similarities with p63 and p73 isoforms. Oncogene 23:631–638.
  • Courtois, S., G. Verhaegh, S. North, M. G. Luciani, P. Lassus, U. Hibner, M. Oren, and P. Hainaut. 2002. DeltaN-p53, a natural isoform of p53 lacking the first transactivation domain, counteracts growth suppression by wild-type p53. Oncogene 21:6722–6728.
  • Dohn, M., S. Zhang, and X. Chen. 2001. p63α and ΔNp63α can induce cell cycle arrest and apoptosis and differentially regulate p53 target genes. Oncogene 20:3193–3205.
  • Donehower, L. A., M. Harvey, B. L. Slagle, M. J. McArthur, C. A. Montgomery, Jr., J. S. Butel, and A. Bradley. 1992. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356:215–221.
  • el-Deiry, W. S., S. E. Kern, J. A. Pietenpol, K. W. Kinzler, and B. Vogelstein. 1992. Definition of a consensus binding site for p53. Nat. Genet. 1:45–49.
  • Espinosa, J. M., and B. M. Emerson. 2001. Transcriptional regulation by p53 through intrinsic DNA/chromatin binding and site-directed cofactor recruitment. Mol. Cell 8:57–69.
  • Firth, S. M., and R. C. Baxter. 2002. Cellular actions of the insulin-like growth factor binding proteins. Endocr. Rev. 23:824–854.
  • Flaman, J. M., F. Waridel, A. Estreicher, A. Vannier, J. M. Limacher, D. Gilbert, R. Iggo, and T. Frebourg. 1996. The human tumour suppressor gene p53 is alternatively spliced in normal cells. Oncogene 12:813–818.
  • Friedlander, P., Y. Haupt, C. Prives, and M. Oren. 1996. A mutant p53 that discriminates between p53-responsive genes cannot induce apoptosis. Mol. Cell. Biol. 16:4961–4971.
  • Gaiddon, C., M. Lokshin, J. Ahn, T. Zhang, and C. Prives. 2001. A subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain. Mol. Cell. Biol. 21:1874–1887.
  • Ghosh, A., D. Stewart, and G. Matlashewski. 2004. Regulation of human p53 activity and cell localization by alternative splicing. Mol. Cell. Biol. 24:7987–7997.
  • Gucev, Z. S., Y. Oh, K. M. Kelley, and R. G. Rosenfeld. 1996. Insulin-like growth factor binding protein 3 mediates retinoic acid- and transforming growth factor beta2-induced growth inhibition in human breast cancer cells. Cancer Res. 56:1545–1550.
  • Halazonetis, T. D., L. J. Davis, and A. N. Kandil. 1993. Wild-type p53 adopts a “mutant”-like conformation when bound to DNA. EMBO J. 12:1021–1028.
  • Harms, K., S. Nozell, and X. Chen. 2004. The common and distinct target genes of the p53 family transcription factors. Cell. Mol. Life Sci. 61:822–842.
  • Hupp, T. R., D. W. Meek, C. A. Midgley, and D. P. Lane. 1992. Regulation of the specific DNA binding function of p53. Cell 71:875–886.
  • Jayaraman, J., and C. Prives. 1995. Activation of p53 sequence-specific DNA binding by short single strands of DNA requires the p53 C-terminus. Cell 81:1021–1029.
  • Juan, L. J., W. J. Shia, M. H. Chen, W. M. Yang, E. Seto, Y. S. Lin, and C. W. Wu. 2000. Histone deacetylases specifically down-regulate p53-dependent gene activation. J. Biol. Chem. 275:20436–20443.
  • Kaghad, M., H. Bonnet, A. Yang, L. Creancier, J. C. Biscan, A. Valent, A. Minty, P. Chalon, J. M. Lelias, X. Dumont, P. Ferrara, F. McKeon, and D. Caput. 1997. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 90:809–819.
  • Kim, H. S., A. R. Ingermann, J. Tsubaki, S. M. Twigg, G. E. Walker, and Y. Oh. 2004. Insulin-like growth factor-binding protein 3 induces caspase-dependent apoptosis through a death receptor-mediated pathway in MCF-7 human breast cancer cells. Cancer Res. 64:2229–2237.
  • Ko, L. J., and C. Prives. 1996. p53: puzzle and paradigm. Genes Dev. 10:1054–1072.
  • Kubbutat, M. H., and K. H. Vousden. 1997. Proteolytic cleavage of human p53 by calpain: a potential regulator of protein stability. Mol. Cell. Biol. 17:460–468.
  • Kulesz-Martin, M. F., B. Lisafeld, H. Huang, N. D. Kisiel, and L. Lee. 1994. Endogenous p53 protein generated from wild-type alternatively spliced p53 RNA in mouse epidermal cells. Mol. Cell. Biol. 14:1698–1708.
  • Lane, D. 2001. How cells choose to die. Nature 414:25, 27.
  • Lin, J., J. Chen, B. Elenbaas, and A. J. Levine. 1994. Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein. Genes Dev. 8:1235–1246.
  • Liu, G., S. Nozell, H. Xiao, and X. Chen. 2004. ΔNp73β is active in transactivation and growth suppression. Mol. Cell. Biol. 24:487–501.
  • Liu, G., T. Xia, and X. Chen. 2003. The activation domains, the proline-rich domain, and the C-terminal basic domain in p53 are necessary for acetylation of histones on the proximal p21 promoter and interaction with p300/CREB-binding protein. J. Biol. Chem. 278:17557–17565.
  • Mee, T., A. L. Okorokov, S. Metcalfe, and J. Milner. 1999. Proteolytic cleavage of p53 mutants in response to mismatched DNA. Br. J. Cancer 81:212–218.
  • Michalovitz, D., O. Halevy, and M. Oren. 1990. Conditional inhibition of transformation and of cell proliferation by a temperature-sensitive mutant of p53. Cell 62:671–680.
  • Mills, A. A., B. Zheng, X. J. Wang, H. Vogel, D. R. Roop, and A. Bradley. 1999. p63 is a p53 homologue required for limb and epidermal morphogenesis. Nature 398:708–713.
  • Molinari, M., A. L. Okorokov, and J. Milner. 1996. Interaction with damaged DNA induces selective proteolytic cleavage of p53 to yield 40 kDa and 35 kDa fragments competent for sequence-specific DNA binding. Oncogene 13:2077–2086.
  • Nozell, S., Y. Wu, K. McNaughton, G. Liu, A. Willis, J. C. Paik, and X. Chen. 2003. Characterization of p73 functional domains necessary for transactivation and growth suppression. Oncogene 22:4333–4347.
  • Okorokov, A. L., F. Ponchel, and J. Milner. 1997. Induced N- and C-terminal cleavage of p53: a core fragment of p53, generated by interaction with damaged DNA, promotes cleavage of the N terminus of full-length p53, whereas ssDNA induces C-terminal cleavage of p53. EMBO J. 16:6008–6017.
  • Olivier, M., R. Eeles, M. Hollstein, M. A. Khan, C. C. Harris, and P. Hainaut. 2002. The IARC TP53 database: new online mutation analysis and recommendations to users. Hum. Mutat. 19:607–614.
  • Osada, M., M. Ohba, C. Kawahara, C. Ishioka, R. Kanamaru, I. Katoh, Y. Ikawa, Y. Nimura, A. Nakagawara, M. Obinata, and S. Ikawa. 1998. Cloning and functional analysis of human p51, which structurally and functionally resembles p53. Nat. Med. 4:839–843.
  • Pariat, M., S. Carillo, M. Molinari, C. Salvat, L. Debussche, L. Bracco, J. Milner, and M. Piechaczyk. 1997. Proteolysis by calpains: a possible contribution to degradation of p53. Mol. Cell. Biol. 17:2806–2815.
  • Polyak, K., Y. Xia, J. L. Zweier, K. W. Kinzler, and B. Vogelstein. 1997. A model for p53-induced apoptosis. Nature 389:300–305.
  • Qian, H., T. Wang, L. Naumovski, C. D. Lopez, and R. K. Brachmann. 2002. Groups of p53 target genes involved in specific p53 downstream effects cluster into different classes of DNA binding sites. Oncogene 21:7901–7911.
  • Ronen, D., D. Schwartz, Y. Teitz, N. Goldfinger, and V. Rotter. 1996. Induction of HL-60 cells to undergo apoptosis is determined by high levels of wild-type p53 protein whereas differentiation of the cells is mediated by lower p53 levels. Cell Growth Differ. 7:21–30.
  • Ryan, K. M., and K. H. Vousden. 1998. Characterization of structural p53 mutants which show selective defects in apoptosis but not cell cycle arrest. Mol. Cell. Biol. 18:3692–3698.
  • Sakamuro, D., P. Sabbatini, E. White, and G. C. Prendergast. 1997. The polyproline region of p53 is required to activate apoptosis but not growth arrest. Oncogene 15:887–898.
  • Saller, E., E. Tom, M. Brunori, M. Otter, A. Estreicher, D. H. Mack, and R. Iggo. 1999. Increased apoptosis induction by 121F mutant p53. EMBO J. 18:4424–4437.
  • Samuels-Lev, Y., D. J. O'Connor, D. Bergamaschi, G. Trigiante, J. K. Hsieh, S. Zhong, I. Campargue, L. Naumovski, T. Crook, and X. Lu. 2001. ASPP proteins specifically stimulate the apoptotic function of p53. Mol. Cell 8:781–794.
  • Schedlich, L. J., and L. D. Graham. 2002. Role of insulin-like growth factor binding protein-3 in breast cancer cell growth. Microsc. Res. Tech. 59:12–22.
  • Sedarous, M., E. Keramaris, M. O'Hare, E. Melloni, R. S. Slack, J. S. Elce, P. A. Greer, and D. S. Park. 2003. Calpains mediate p53 activation and neuronal death evoked by DNA damage. J. Biol. Chem. 278:26031–26038.
  • Selivanova, G., V. Iotsova, I. Okan, M. Fritsche, M. Strom, B. Groner, R. C. Grafstrom, and K. G. Wiman. 1997. Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 C-terminal domain. Nat. Med. 3:632–638.
  • Selivanova, G., L. Ryabchenko, E. Jansson, V. Iotsova, and K. G. Wiman. 1999. Reactivation of mutant p53 through interaction of a C-terminal peptide with the core domain. Mol. Cell. Biol. 19:3395–3402.
  • Shaw, P., J. Freeman, R. Bovey, and R. Iggo. 1996. Regulation of specific DNA binding by p53: evidence for a role for O-glycosylation and charged residues at the carboxy-terminus. Oncogene 12:921–930.
  • Tokino, T., S. Thiagalingam, W. S. el-Deiry, T. Waldman, K. W. Kinzler, and B. Vogelstein. 1994. p53 tagged sites from human genomic DNA. Hum. Mol. Genet. 3:1537–1542.
  • Trink, B., K. Okami, L. Wu, V. Sriuranpong, J. Jen, and D. Sidransky. 1998. A new human p53 homologue. Nat. Med. 4:747–748.
  • Venot, C., M. Maratrat, C. Dureuil, E. Conseiller, L. Bracco, and L. Debussche. 1998. The requirement for the p53 proline-rich functional domain for mediation of apoptosis is correlated with specific PIG3 gene transactivation and with transcriptional repression. EMBO J. 17:4668–4679.
  • Venot, C., M. Maratrat, V. Sierra, E. Conseiller, and L. Debussche. 1999. Definition of a p53 transactivation function-deficient mutant and characterization of two independent p53 transactivation subdomains. Oncogene 18:2405–2410.
  • Walker, K. K., and A. J. Levine. 1996. Identification of a novel p53 functional domain that is necessary for efficient growth suppression. Proc. Natl. Acad. Sci. USA 93:15335–15340.
  • Yang, A., M. Kaghad, Y. Wang, E. Gillett, M. D. Fleming, V. Dotsch, N. C. Andrews, D. Caput, and F. McKeon. 1998. p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol. Cell 2:305–316.
  • Yang, A., and F. McKeon. 2000. p63 and p73: p53 mimics, menaces and more. Nat. Rev. Mol. Cell Biol. 1:199–207.
  • Yang, A., N. Walker, R. Bronson, M. Kaghad, M. Oosterwegel, J. Bonnin, C. Vagner, H. Bonnet, P. Dikkes, A. Sharpe, F. McKeon, and D. Caput. 2000. p73-deficient mice have neurological, pheromonal and inflammatory defects but lack spontaneous tumours. Nature 404:99–103.
  • Zheng, X., and X. Chen. 2001. Aquaporin 3, a glycerol and water transporter, is regulated by p73 of the p53 family. FEBS Lett. 489:4–7.
  • Zhu, J., J. Jiang, W. Zhou, K. Zhu, and X. Chen. 1999. Differential regulation of cellular target genes by p53 devoid of the PXXP motifs with impaired apoptotic activity. Oncogene 18:2149–2155.
  • Zhu, J., S. Nozell, J. Wang, J. Jiang, W. Zhou, and X. Chen. 2001. p73 cooperates with DNA damage agents to induce apoptosis in MCF7 cells in a p53-dependent manner. Oncogene 20:4050–4057.
  • Zhu, J., S. Zhang, J. Jiang, and X. Chen. 2000. Definition of the p53 functional domains necessary for inducing apoptosis. J. Biol. Chem. 275:39927–39934.
  • Zhu, J., W. Zhou, J. Jiang, and X. Chen. 1998. Identification of a novel p53 functional domain that is necessary for mediating apoptosis. J. Biol. Chem. 273:13030–13036.
  • Zilfou, J. T., W. H. Hoffman, M. Sank, D. L. George, and M. Murphy. 2001. The corepressor mSin3a interacts with the proline-rich domain of p53 and protects p53 from proteasome-mediated degradation. Mol. Cell. Biol. 21:3974–3985.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.